Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2025-12-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in their securities, including share capital, share options, and treasury shares. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Director's Dealing' or 'Share Issue' (as it is a summary report of all movements), it is classified as a Regulatory Filing.
2025-12-04 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 82% confidence The document is the full text of the monthly FF301 return filed to HKEX under Chapter 19B listing rules, detailing authorised/issued share capital movements, share options, and confirmations. It is not an earnings release, annual or interim report, proxy statement, or other specific category; rather, it is a routine regulatory submission for share capital movements. Therefore it falls under the fallback “Regulatory Filings” category.
2025-11-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Share Issue/Capital Change Classification · 80% confidence The document is a regulatory listing‐rule monthly return (Form FF301) submitted to HKEX detailing movements in authorized share capital, issued shares, share options, and other capital changes for the month ended 30 September 2025. It is not an earnings release, management discussion, or dividend notice but is specifically an announcement of share capital movements. The most appropriate category is Share Issue/Capital Change (SHA).
2025-10-06 English
Interim Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT' (中期報告) for 3D Medicines Inc. for the period ended June 30, 2025. It contains comprehensive sections including Business Highlights, Financial Summary, Management Discussion and Analysis, and full Interim Condensed Consolidated Financial Statements (Profit or Loss, Financial Position, Changes in Equity, Cash Flows, and Notes). This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-30 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Regulatory Filings Classification · 85% confidence The document is a Hong Kong Exchange (HKEX) listing rule compliance return (FF301) detailing monthly movements in share capital, issued shares, options, etc. It is a standard regulatory submission under Chapter 19B of the Listing Rules rather than an earnings release, proxy, or capital raising announcement. This fits the “Regulatory Filings” fallback category (RNS).
2025-09-04 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025' and contains detailed unaudited condensed consolidated financial statements, business highlights, and a management discussion and analysis (MDA) section for the specified interim period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-29 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.